SOHO ANNUAL MEETING 2024

PRIMARY CNS LYMPHOMA IN CHILDREN "CURRENT MANAGEMENT STRATEGIES AND IMPACT ON PATIENT SURVIVAL"

Magda Elgazzar[1] Asmaa Hamoda[1,2] , Hanaa Rashad[1] , Eman Nageb[1] , Iman Zaki[1] ,Ahmed Mosa[1] , Hany Abderhman[1,2]
(1) Children's Cancer Hospital ,Cairo ,Egypt
(2) National Cancer Institute, Cairo University, Egypt

57357

INTRODUCTION

Primary Central Nervous system lymphoma (PCNSL) is a rare extra nodal lymphomatous malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement.

AIM

We intended to describe the clinical presentation , the approach of work-up, and current treatment strategy PCNSL and its outcome .


METHOD

Inclusion criteria:
Patients < 18 ys diagnosed with lymphoma in the brain or spinal cord who were treated at Children Cancer Hospital Egypt in the period between July 2012----June 2022
Exclusion criteria:
Patient with nodal disease with CNS involvement.

RESULTS

9 cases were recruited at CCHE 57357 in the period between 2007 and 2022.Five cases were diagnosed as Burritt's lymphoma (55.6%) and 4 cases were diagnosed as diffuse large B cell lymphoma (DLBL) (44.4%) , with a male: female ratio 2:1 , aand median age 12 years (range from 2-18 years). CSF cytology for the studied patients was positive in only one case (11.1%) and negative in 8 cases (88.9%). Treatment received was LMB protocol in 4 cases (44.4%) and 5 cases underwent surgery followed by LMB protocol (55.6%).

Outcome of the 9 cases; 5 cases are live in CR (55.6%), 1 case lives in active disease (11.1%) and 3 cases (33.3%) died out of progressive disease.



CONCLUSIONS

Outcomes in recent series are similar to that of systemic NHL with CNS disease with 3-year overall survival (OS) of 62% .Usage of high-dose methotrexate and high-dose cytarabine were associated with improved prognosis. Recent developments in the understanding of the pathogenesis of primary CNS Lymphoma (PCNS)L have led to the investigation and use of new, targeted approaches.

REFERENCES

- Omuro AMP, DeAngelis LM, Karrison T, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol. 2020;38(15 suppl):2501.
- Krebs S, Barasch JG, Young RJ, Grommes C, Schöde r H, Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review. Ann Lymphoma. 2021;5:15.

CONTACT INFORMATION

Magda Elgazzar

Pediatric oncologist at CCHE, 57357

Mail: Magda.elgazzar@57357.org

TEL:+201003502822